Immune Checkpoint Blockers and Ovarian Cancer. - Wikidata - wikimedia - TriplyDB

Immune Checkpoint Blockers and Ovarian Cancer.

Immune Checkpoint Blockers and Ovarian Cancer.

http://www.wikidata.org/entity/Q41601825

about

Immune Checkpoint Blockers and Ovarian Cancer.

http://www.wikidata.org/entity/Q41601825

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Immune Checkpoint Blockers and Ovarian Cancer.

@en

type

label

Immune Checkpoint Blockers and Ovarian Cancer.

@en

prefLabel

Immune Checkpoint Blockers and Ovarian Cancer.

@en

P1433

Q41601825-CF3C63B7-AC61-4354-ADE0-510168F30E7A

P1476

Q41601825-5102D819-F426-48A8-8134-5883C8E6D267

P2093

Q41601825-EDEB229A-30E0-4715-B16B-6018D5C59902

P2860

Q41601825-01318F1A-2C52-4761-9AB6-54DD83ECD271

Q41601825-1B9E75E5-AFF5-4C66-8C14-DDA4DBEF46E5

Q41601825-1C5CB9ED-5344-4CC8-8983-90D59BAEAB8E

Q41601825-1F75D648-D205-4B96-96AA-F436468DEFC4

Q41601825-27133F10-EF48-4FB2-9252-DA9DE55B442F

Q41601825-2D53976F-B470-44BB-9ADC-D23CD5BFF944

Q41601825-32CB2BCB-D752-4DD8-BC4E-27BBD8FA6AD1

Q41601825-339E6F0B-CFFE-4988-BE1B-B7B551830C24

Q41601825-41750498-4B75-4A1A-B564-C48DDC6DFF48

Q41601825-4562A7B5-23B6-4068-BA6D-E339C218468E

P304

Q41601825-2F060DF4-AD69-4FE9-B79B-4F81E82E9D6F

P31

Q41601825-E8DD6460-FACA-4701-8313-892B4231D9F1

P356

Q41601825-0D4340FF-8614-43EC-9372-3F0AEF15C336

P433

Q41601825-434ACDBC-C82B-4663-8CE2-2EADB89F9E17

P478

Q41601825-F7FFF286-548A-42C7-B9D7-B7FECF4A3196

P577

Q41601825-4CD4ABF0-5DB6-493D-950B-BFC0997EF47A

P698

Q41601825-6887C99C-449A-47DA-8D28-68161D34B9E4

P932

Q41601825-0C046D2C-7D40-4B22-8BD8-4CA3CD560387

P356

IJMPO.IJMPO_73_16

P1433

Indian Journal of Medical and Paediatric Oncology

P1476

Immune Checkpoint Blockers and Ovarian Cancer.

@en

P2093

Chinmoy K Bose

http://www.w3.org/2001/XMLSchema#string

P2860

CD28/B7 system of T cell costimulation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Inflammation and cancer: back to Virchow?

P304

182-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJMPO.IJMPO_73_16

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28900328

http://www.w3.org/2001/XMLSchema#string

P932

5582557

http://www.w3.org/2001/XMLSchema#string